Enliven Therapeutics, Inc. (ELVN) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ELVN Revenue Growth
ELVN Revenue Analysis (2017–2025)
As of May 8, 2026, Enliven Therapeutics, Inc. (ELVN) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, ELVN's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), and AUPH (+20.4% YoY). Compare ELVN vs KYMR →
ELVN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ELVNCurrent | $0 | - | - | - | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 AUPH | $283M | +20.4% | +41.4% | 37.1% |
ELVN Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-263,000 | - | $-119,658,000 | - |
| 2024 | $0 | - | $0 | - | $-104,554,000 | - |
| 2023 | $0 | - | $0 | - | $-83,529,000 | - |
| 2022 | $0 | - | $0 | - | $-38,791,000 | - |
| 2021 | $0 | - | $0 | - | $-24,762,000 | - |
| 2020 | $0 | - | $0 | - | $-9,318,000 | - |
| 2019 | $0 | - | $-33,000 | - | $-24,116,000 | - |
| 2018 | $0 | - | $0 | - | $-10,677,000 | - |
| 2017 | $0 | - | $0 | - | $-8,905,000 | - |
See ELVN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ELVN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ELVN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonELVN — Frequently Asked Questions
Quick answers to the most common questions about buying ELVN stock.
Is ELVN's revenue growth accelerating or slowing?
ELVN TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ELVN's long-term revenue growth rate?
Enliven Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is ELVN's revenue distributed by segment?
ELVN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.